Company intelligence / Profile preview

InvisiShield Technologies Ltd.

Emeryville, California, United Statesinvisishieldtech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

In preclinical studies, InvisiShield's engineered intranasal antibodies have effectively neutralized respiratory viruses. Their IS101 candidate has shown robust protection against SARS-CoV-2 variants and has demonstrated disruption of viral transmission in Syrian golden hamster models. IS101 provided at least 10 hours of protection against infection in mice.

Therapeutic areas: Infectious Diseases
Modalities: Engineered intranasal antibodiesantibody fusion proteins
Industry: Biotech

Drug pipeline

1 asset

IS-101

Preclinical

Partnerships

Gladstone InstitutesEureka Therapeutics

Beyond the preview

Go deeper on InvisiShield Technologies Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InvisiShield Technologies Ltd..

Explore the full profile